Increased levels of activated factor VII and decreased plasma protein S activity and circulating thrombomodulin during use of oral contraceptives.

Article Details

Citation

Copy to clipboard

Quehenberger P, Loner U, Kapiotis S, Handler S, Schneider B, Huber J, Speiser W

Increased levels of activated factor VII and decreased plasma protein S activity and circulating thrombomodulin during use of oral contraceptives.

Thromb Haemost. 1996 Nov;76(5):729-34.

PubMed ID

8950781 [ View in PubMed

]

Abstract

In the present study the effect of oral contraceptive (OC) treatment on selected factors involved in the activation, i.e. circulating activated factor VII (cFVIIa), and in the inhibition of blood coagulation, i.e. plasma protein S activity and circulating thrombomodulin (cTM), were for the first time measured in OC users in a prospective study. Beside other coagulation variables, these parameters were measured during treatment with three low estrogen formulations containing different gestagen components (norgestimate, gestodene). During OC treatment increases in the activation markers prothrombin fragment F1 + 2 and D-Dimer were found, suggesting an increased activation of blood coagulation and fibrinolysis. Along with elevated plasma levels of FVII antigen, cFVIIa was also found increased in all three treatment groups, while inhibitory components of blood coagulation, plasma protein S activity and cTM, significantly and similarly decreased during treatment in all three treatment groups. We conclude that low dose estrogen pills induce similar changes in the plasma levels of main regulatory components of blood coagulation, despite differences in their gestagen components. Increased levels of activators and decreased activities of inhibitors may contribute to arterial and venous thrombotic complications seen in predisposed OC users.

DrugBank Data that Cites this Article

Pharmaco-proteomics

Drug	Drug Groups	Gene	Gene ID	Change	Interaction	Chromosome
Ethinylestradiol	Approved	THBD	7056	decreased	Ethinyl Estradiol results in decreased expression of THBD protein	20p11.21
Ethinylestradiol	Approved	F2	2147	increased	Ethinyl Estradiol results in increased expression of F2 protein	11p11.2
Ethinylestradiol	Approved	F7	2155	increased	Ethinyl Estradiol results in increased expression of F7 protein	13q34
Ethinylestradiol	Approved	PROS1	5627	decreased	Ethinyl Estradiol results in decreased expression of PROS1 protein	3q11.1
Ethinylestradiol	Approved	PROS1	5627	decreased	Ethinyl Estradiol results in decreased expression of PROS1 protein	3q11.1